# Electroconvulsive Therapy Modulates Loudness Dependence of Auditory Evoked Potentials: A Pilot MEG Study

Michael Dib  $^1$ , Jeffrey D. Lewine  $^{2,3}$ , Christopher C. Abbott  $^{3,\dagger}$ , Zhi-De Deng  $^{4,\dagger,*}$ 

<sup>1</sup>*Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA* 

<sup>2</sup> The Mind Research Network, University of New Mexico, Albuquerque, NM, USA <sup>3</sup> Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA

<sup>4</sup>Computational Neurostimulation Research Program, Noninvasive Neuromodulation Unit, Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health Intramural Research Program, National Institutes of Health, Bethesda, MD, USA

<sup>†</sup>These authors share senior authorship

Correspondence\*: Zhi-De Deng zhi-de.deng@nih.gov

## 2 ABSTRACT

1

Electroconvulsive therapy (ECT) remains a critical intervention for treatment-resistant 3 depression (MDD), yet its neurobiological underpinnings are not fully understood. This pilot study 4 utilizes high-resolution magnetoencephalography (MEG) in nine depressed patients receiving right 5 unilateral ECT, to investigate the changes in loudness dependence of auditory evoked potentials 6 (LDAEP), a proposed biomarker of serotonergic activity, following ECT. We hypothesized that 7 ECT would reduce the LDAEP slope, reflecting enhanced serotonergic neurotransmission. 8 Contrary to this, our findings indicated a significant increase in LDAEP post-ECT ( $t_8 = 3.17$ , 9 p = .013). The increase in LDAEP was not associated with changes in depression severity or 10 cognitive performance, as assessed by the Hamilton Depression Rating Scale (HAMD-24) and 11 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). We discussed 12 potential mechanisms for the observed increase, including ECT's impact on serotonergic, 13 dopaminergic, glutamatergic, and GABAergic receptor activity, neuroplasticity involving brain-14 derived neurotrophic factor (BDNF), and inflammation modulators such as TNF-alpha. Our results 15 16 suggest a complex interaction between ECT and these neurobiological systems, rather than a 17 direct reflection of serotonergic neurotransmission.

18 Keywords: Electroconvulsive therapy, Loudness depedence of auditory evoked potentials, major depressive disorder,
 19 magnetoencephalography, serotonin

#### **1 INTRODUCTION**

Major depressive disorder (MDD) remains a pervasive global health challenge, affecting millions worldwide 20 and ranking among the leading causes of disability. MDD leads to substantial healthcare costs and 21 contributing heavily to the overall disease burden (1). Despite the widespread use of antidepressant 22 23 medications, many patients do not achieve sustained relief. As an alternative, neuromodulation therapies such as electroconvulsive therapy (ECT) play a vital role. ECT is a well-established intervention that 24 25 demonstrates exceptional efficacy in multiple psychiatric disorders, including MDD. It involves the 26 administration of electrical currents, either unilateral or bilateral electrode placements on the patient's head, to induce a brief, controlled seizure. Ultimately, this process is thought to elicit reorganization of 27 key cortical networks involved with mood and cognition. However, ECT can cause significant adverse 28 effects, such as memory loss and confusion, rendering ECT to be reserved for severely treatment resistant 29 patients (2, 3). entifying the specific neurophysiological changes induced by ECT could lead to the 30 development of safer and more effective treatments. While the optimal stimulation methods and parameters 31 32 are still being investigated, ECT remains essential for managing treatment-resistant depression.

More than eight decades have passed since its introduction as a clinical intervention, the precise 33 neurobiological mechanisms underpinning ECT's therapeutic effect remain elusive. Current research 34 suggests that ECT's benefits are likely achieved through multiple mechanisms. These include, but are 35 not limited to, changes in neurotransmitter transmission, enhancement of neurotrophic and neuroplastic 36 37 activities, modulation of cortical networks, reduction of neuroinflammation, and regulation of the endocrine system. (3, 4, 5, 6, 7, 8, 9, 10). Given the historical precedence of the monoaminergic theory of depression, 38 a plethora of studies in both animals and humans have sought out to determine whether ECT's efficacy 39 is related to changes in serotonergic activity (11, 12). While the evidence remains inconclusive, ECT 40 appears to have some notable effect on serotonergic neurotransmission (3). A significant challenge in this 41 area is that peripheral biomarker measurements do not reliably reflect neurotransmitter levels in the brain. 42 Advanced neuroimaging techniques can be employed to gather insight into the effect of treatments such as 43 ECT on neurotransmitter activity. 44

45 Loudness dependence of auditory evoked potentials (LDAEP) is a method used to measure the response of 46 cortical potentials to variations in the intensity (i.e., loudness) of auditory stimuli. The relationship between stimuli loudness and evoked potential amplitudes in the primary auditory cortex has been suggested as 47 48 an indicator of serotonergic neurotransmission (13). Initial studies in animal models reported that higher 49 serotonin activity was correlated with less dependence on stimulus intensity (i.e., similar amplitudes in cortical evoked potentials regardless of loudness). Conversely, lower serotonin activity was correlated 50 51 with loudness-dependent changes in evoked potential amplitudes (13, 14). Furthermore, LDAEP has been proposed to be a protective mechanism in auditory processing, which helps prevent overstimulation and 52 excitotoxicity (15). Within the primary auditory cortex, the neurobiological mechanisms of a reduced 53 LDAEP being associated with high serotonin activity is proposed to rely on serotonergic modulation 54 of cortical excitability. This modulation occurs indirectly via GABA-ergic interneurons, which express 55 excitatory 5-HT2A receptors, and directly via pyramidal cells, which express both excitatory 5-HT2A and 56 inhibitory 5-HT1A receptors (13, 14, 16, 17). 57

An abundance of literature now exists exploring the relationship between the LDAEP and other neurotransmitter systems and biomarkers (18, 19). While evidence for the LDAEP's relationship with serotonin is controversial, it is clear serotonergic activity serves a critical role in the functioning of the primary auditory cortex (18, 20, 21, 22, 23, 24). Numerous studies provide robust support for the influence of serotonergic activity on neuronal functioning across auditory processing pathways (25, 26, 27, 28). Notably, a recent positron emission tomography (PET) study on the molecular mechanisms underlying
the LDAEP reported that this biomarker is strongly and positively correlated with 5-HT1A binding in the
temporal cortex, specifically in the location of the primary auditory cortex (29).

66 Additionally, studies have demonstrated that serotonin plays a crucial role at the intersection of psychiatric disorders and auditory conditions, including tinnitus and hearing loss (25, 26). In particular, MDD has 67 been reported to be associated with impaired auditory processing. Studies indicate that deviations in 68 69 serotonergic activity are evident in the auditory cortices of individuals with depression compared to controls (23, 30, 31, 32, 33). For example, increased 5-HT1A binding and decreased 5-HT2A binding 70 specifically within the primary auditory cortex in depressed patients has been reported (23). Moreover, 71 treatments for depression, including ECT, have been shown to have a significant effect on auditory 72 73 processing, demonstrated via increased activity, excitability, and intrinsic connectivity within the auditory 74 cortices (30, 31, 34, 35, 36). Additionally, ECT has shown a pronounced impact on auditory evoked 75 potentials, further underscoring the complex interplay between serotonergic modulation and auditory 76 functions in psychiatric contexts (37, 38).

Given the efficacy of serotonergic agents such as selective serotonin reuptake inhibitors, and more recently 77 psychedelics like psilocybin, in the treatment of depression, it is likely regulation of this monoamine 78 system serves a pivotal role in ECT's efficacy (39). Studies show mixed results regarding ECT's impact 79 on serotonergic receptors. For instance, some reports indicate that electroconvulsive stimuli result in 80 decreased binding and activity of both 5-HT1A and 5-HT2A receptors (12, 40, 41, 42). However, other 81 studies reveal no change in 5-HT1A activity, an increase in 5-HT2 activity, and enhanced serotonin 82 transporter (SERT) receptor levels following ECT (43, 44, 45, 46). Despite these discrepancies, there 83 is broad consensus that ECT has a robust impact on serotonergic receptors in the treatment of multiple 84 psychiatric disorders (8, 12, 47, 48). 85

This study utilizes high-resolution magnetoencephalography (MEG) to measure cortical activity and determine the LDAEP in individuals before and after ECT. The primary aim is to explore the changes in the central serotonergic neurotransmission attributable to ECT, by analyzing variations in LDAEP. We hypothesize that ECT will decrease LDAEP, indicative of enhanced serotonergic neurotransmission. This approach not only promises to deepen our understanding of the neurochemical environment in patients undergoing ECT but also sheds light on the neurobiological mechanisms that underpin ECT's effectiveness.

## 2 METHODS

Study participants and ECT treatment Ethical approval was obtained from the Human Research Protections 92 93 Office at the University of New Mexico (UNM) before study initiation. The research was conducted in full compliance with the ethical standards outlined in the Declaration of Helsinki. Patients were recruited from 94 95 the UNM Mental Health Center's inpatient and outpatient services. All patients either had the decisional capacity to consent or, where necessary, provided assent with a surrogate decision-maker giving formal 96 97 consent. Prior to receiving treatment, the average score on the 24-item Hamilton Depression Rating Scale 98 (HAMD-24) for these patients was 37.2 (12.8). Additionally, the mean score on the total Repeatable Battery 99 for the Assessment of Neuropsychological Status (RBANS) was 82.9 (19.4). All patients completed a full course of electroconvulsive therapy (ECT) using the ultra-brief pulse width, right unilateral electrode 100 placement as previously described (49). During the initial session, the seizure threshold was determined 101 102 using a dose titration method, which then guided the dosage for subsequent treatments. Specifically, the stimulus dosage was set at six times the threshold. Treatments were administered thrice weekly, and 103

104 continued until an adequate clinical response was achieved or a decision was made to cease treatment due105 to non-response.

#### 106 2.1 MRI

All MRI scans were conducted using the 3-Tesla Siemens Trio scanner at the Mind Research Network (MRN). High-resolution T1-weighted structural images were acquired using a 5-echo MPRAGE sequence with the following parameters: echo times (TE) of 1.64, 3.5, 5.36, 7.22, and 9.08 ms; repetition time (TR) of 2.53 s; inversion time (TI) of 1.2 s; a flip angle of 7°; a single excitation; a slice thickness of 1 mm; a field of view of 256 mm; and a resolution of  $256 \times 256$ . Structural MRI preprocessing and the delineation of structural images were conducted using FreeSurfer 4.5.0 software (https://surfer.nmr.mgh. harvard.edu) (50).



**Figure 1.** Workflow of MEG acquisiton and data processing, detailing the steps from signal acquisition to data analysis. It shows the MEG setup, signal preprocessing, auditory stimulus presentation, data normalization, brain activity source localization, and the quantification of auditory evoked potentials (AEPs) across different sound intensity levels.

#### 114 2.2 MEG acquisition and data processing

Prior to and following the ECT course, patients underwent MEG scans (see Figure 1). MEG recordings were captured using the Elektra Neuromag VectorView 306 system, which is equipped with 102 magnetometers and 204 planar gradiometers. To ensure accurate alignment, the MRIs were coregistered with scalp fiducial markers. While seated inside the MEG helmet, patients were exposed to a series of auditory tones at five different intensity levels: 55, 65, 75, 85, and 95 dB. The tones were emitted through biauricular earbuds at a frequency of 2 kHz, lasting 50 ms each. The tones were presented in a random sequence, with each intensity block comprising 22 tones, resulting in a total of 110 trials per intensity level.

Data analysis was performed with Brainstorm 3 (51), which is documented and freely available for download online under the GNU general public license (http://neuroimage.usc.edu/ brainstorm). The MEG data was filtered using a 1–100 Hz bandpass filter and a 60 Hz notch filter to eliminate electrical line noise. Malfunctioning channels were identified and excluded. Artifacts arising from cardiac activity and eye blinks were removed via signal-space projection, and independent component analysis was used to eliminate other non-brain artifacts. Auditory events were defined for a time window from -100 to  $500 \,\mathrm{ms}$  around the tone's presentation. The data was normalized using the Z-transformation relative to the  $100 \,\mathrm{ms}$  pre-stimulus baseline.

130 Cortical structures were derived from each subject's MRI scans using FreeSurfer, and aligned with 131 a standard brain atlas for cortical reconstruction. The head model for the forward model utilized the symmetric boundary element method (BEM) implemented in OpenMEEG, provided by the INRIA institute. 132 This model established a computational link between the neuronal activity in the source space and the 133 134 recorded MEG data in the sensor space, considering the conductive properties of head tissues. The inverse model, which infers neural activity from the MEG data, was computed using a data covariance matrix 135 through the linearly constrained minimum variance (LCMV) beamforming technique, focusing on auditory 136 137 evoked potentials. Trial-averaged, source-level event-related fields (ERFs) were extracted from the bilateral primary auditory cortices. Finally, the LDAEP was calculated by evaluating the change in normalized 138 ERF amplitude between the N100 and P200 components from the trial-averaged epochs. The LDAEP is 139 140 represented by the slope of the linear regression line fitted to these data points.

### 141 2.3 Statistical analysis

We evaluated the distribution of our data for normality using the Shapiro-Wilk test. The tests indicated normality in the changes in the LDAEP slope (p = 0.098), HAMD scores (p = 0.263), and total RBANS scores (p = 0.105). To investigate longitudinal differences in LDAEP slopes, depression scores, and cognitive functioning scores, we employed paired *t*-tests. Additionally, we explored correlations among the pre-treatment and post-treatment LDAEP slopes, the degree of their changes, and the baseline, post-treatment, and changes in HAMD-24 and RBANS scores.

## 3 RESULTS

## 148 3.1 Demographics and clinical outcomes

149 Six of nine patients responded (> 50% reduction in HAMD-24 from baseline) to ECT with an average 150 post-ECT HAMD-24 score of  $9.1 \pm 7.6$  ( $t_8 = 5.60$ , p < .001). We collected seven of the nine patients'

151 RBANS data, and found, on average, their cognitive functioning did not change with ECT ( $t_6 = 0.358$ ,

p = .73). Demographics and clinical measures before and after ECT treatment are summarized in Table 1.

Measure	Pre-ECT (Mean $\pm$ SD)	Post-ECT (Mean $\pm$ SD)	t	<i>p</i> -value
N (no. female)	9 (6)	_	-	
Age, years	$68.1 \pm 10.7$	-	-	
LDAEP	$0.41 \pm 0.64$	$0.75 \pm 0.74$	3.17	.013
HAMD-24	$37.2 \pm 12.8$	$9.1 \pm 7.6$	5.60	< 0.001
RBANS Scores				
Total	$82.9 \pm 19.4$	$84.4 \pm 18.0$	0.36	.73
Immediate memory	$78.0 \pm 25.4$	$83.1 \pm 24.2$	0.84	.44
Visuospatial/Constructional	$84.7\pm26.1$	$90.7 \pm 17.7$	0.79	.46
Language	$92.6\pm8.9$	$89.7\pm8.0$	0.79	.46
Attention	$92.4 \pm 14.7$	$89.6 \pm 17.9$	1.05	.34
Delayed memory	$85.3 \pm 22.1$	$85.7 \pm 22.2$	0.08	.94

Fable 1.	Demographics and	clinical n	neasures befo	ore and after	ECT treatment
----------	------------------	------------	---------------	---------------	---------------

#### 153 3.2 Change in LDAEP

Figure 2 shows the auditory evoked potentials before and after ECT treatment, with responses at varying stimulus loudness levels. The LDAEP slope significantly increased following ECT treatment from  $0.41 \pm 0.64$  to  $0.75 \pm 0.74$ ) (Cohen's d = 0.49,  $t_8 = 3.17$ , p = .013) (Figure 3).



**Figure 2.** Auditory evoked potentials (A) before and (B) after ECT treatment, with responses at sound pressure levels of 55-95 dB. The change in normalized AEP amplitude between the N100 and P200 (N1/P2) components of the trial-averaged epochs was calculated. The LDAEP is calculated as the slope of linear regression line that best fits the N1/P2 amplitudes at each sound pressure level.

156

#### 157 3.3 Correlations between LDAEP and depression and cognition scores

The change in the LDAEP slope was not significantly correlated with baseline (r = -0.079, p = .84), post-treatment (r = 0.066, p = .87), or changes in HAMD-24 scores (r = 0.101, p = .80). The pre-ECT LDAEP slope was not significantly correlated with baseline (r = -0.194, p = .62) nor changes in HAMD-24 scores (r = 0.339, p = .37).

We focused on assessing correlations with RBANS total scores. The change in LDAEP slope was not significantly correlated with the baseline (r = 0.208, p = .66), post-treatment (r = 0.403, p = .37), or changes (r = 0.276, p = .55) in the RBANS total score. The pre-ECT LDAEP slope was significantly correlated with the baseline RBANS total score (r = 0.855, p = .014), but not correlated with changes in the RBANS total score (r = -0.352, p = .44).

#### 4 DISCUSSION

167 In this study, we used LDAEP as a cortical activity biomarker to monitor changes in neurotransmitter 168 activity induced by ECT. Our initial hypothesis posited that ECT would mitigate symptoms of depression 169 by boosting serotonergic neurotransmission, which would manifest as a reduced LDAEP, reflected by 170 weakening of the response amplitude as a function of sound intensity levels. However, our findings revealed



**Figure 3.** Individual changes in the pre- and post-ECT LDAEP slope measure. There was a significant increase post-ECT compared to baseline (Cohen's d = 0.49,  $t_8 = 3.17$ , p = .013).

a significant increase in LDAEP post-ECT. Interestingly, the alterations in LDAEP did not correlate with
 changes in depression severity or cognitive performance.

The neurochemical underpinnings of LDAEP suggest that ECT should lead to a reduction in serotonergic 173 tone within the primary auditory cortex, but this assumption is subject to debate. Studies on the relationship 174 between LDAEP and serotonergic activity have harbored conflicting evidence and perspectives (19, 24, 175 52, 53). While numerous studies have found that the LDAEP is sensitive to acute changes in serotonergic 176 activity, such as following administration of serotonergic-reuptake inhibitors, other studies have presented 177 contrasting findings (54, 55, 56, 57, 58, 59, 60). A recent narrative review by Kangas et. al stated that 178 LDAEP studies have generally yielded no consistent difference between depressed and non-depressed 179 180 controls, though there appears to be a relationship with depression-subtypes (18). Given this context, a possible explanation for our results not supporting the original hypothesis could be that the LDAEP does 181 not precisely mirror serotonergic tone in the primary auditory cortex. 182

183 Our findings did reveal a significant modulation of the LDAEP after ECT treatment. Intriguingly, the 184 observed increase in LDAEP may indicate that ECT prompted a reduction in serotonergic receptor activity within the primary auditory cortex, particularly 5-HT1A and 5-HT2 receptors. This algins with multiple 185 studies demonstrating a reduction in 5-HT2 and 5-HT1A receptors in humans and non-human primates 186 following ECT (40, 41, 42, 61, 62). The initial LDAEP studies in animal models bolster the plausibility of 187 ECT-induced reduction in serotonergic receptors, in that a 5-HT1A agonist decreased the LDAEP and a 188 5-HT2A antagonist increased the LDAEP, suggesting that decreased serotonin receptor activity results in a 189 strengthened LDAEP (13, 63). However, pre-clinical studies have largely found an upregulation of 5-HT1A 190 and 5-HT2A receptors after electroconvulsive stimuli in animal models (44, 46, 64). This discrepancy 191 underscores the need for further research to understand ECT's impact on serotonergic receptor activity in 192 humans more comprehensively. 193

Several alternative explanations as to why the LDAEP increased following ECT may be plausible. The 194 195 LDAEP has been shown to covary with symptom severity in disorders such as ADHD, schizophrenia, and Parkinson's disease, all of which are strongly linked to dopaminergic dysregulation (65, 66, 67). Given 196 that ECT has been found to significantly alter dopaminergic neurotransmission (44, 68, 69, 70, 71), one 197 possible explanation for the heightened LDAEP could be ECT's direct influence on dopamine receptor 198 and transporter activities. Furthermore, considering that the LDAEP results from both excitatory and 199 inhibitory post-synaptic potentials within the primary auditory cortex, the altered LDAEP could reflect 200 changes in glutamatergic and GABAergic functions. Indeed, ECT has been shown to increase GABA 201 concentration, normalize glutamate deficits, and alter excitation/inhibition ratios (26, 72, 73, 74, 75). For 202 instance, the administration of a glutamatergic NMDA antagonist has been reported to blunt LDAEP, 203 suggesting that increased glutamatergic activity correlates with a heightened LDAEP (76). On the other 204 hand, a study reported that the LDAEP is not associated with GABA levels (77). Further exploration of the 205 relationships between ECT, auditory cortical activity, and excitatory and inhibitory neurotransmitters could 206 yield valualbe insights. 207

Beyond neurotransmitter effects, there is a consistent body of evidence indicating that ECT is associated 208 with increased gray matter volume in the temporal lobes, including the superior temporal gyrus (5, 78, 79, 209 80), where the primary auditory cortex is situated. It is possible that neurotrophic effects are related to 210 the increased LDAEP following ECT in this study. A recent meta-analysis concluded that ECT directly 211 increases concentrations of brain-derived neurotrophic factor (BDNF) (81). Similarly, the LDAEP has been 212 found to be significantly positively correlated with serum BDNF levels (82). One possibility is that ECT's 213 robust neuroplastic effects within the temporal lobe are related to the modulation of the LDAEP. Moreover, 214 systematic reviews found that ECT has consistently been reported to decrease levels of inflammatory 215 biomarkers, tumor necrosis factor alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6) (83, 84). Notably, one study 216 demonstrated that the LDAEP was negatively correlated with TNF- $\alpha$  (85). This could suggest that a 217 reduction in TNF- $\alpha$  might contribute to the LDAEP increase seen after ECT. Given these multifaceted 218 biological interactions, further research is indeed warranted to unravel the complexities of ECT's impact 219 on the LDAEP and underlying neurobiological mechanisms. 220

In terms of cognitive performance, our study found that the pre-ECT LDAEP correlated with baseline RBANS total scores. However, change in LDAEP was not associated with changes in cognitive performance post-ECT. While the reasons for these findings warrant further investigation, our preliminary data does suggest a link between LDAEP and cognitive performance metrics.

Finally, it is crucial to acknowledge the limitations inherent in this pilot study. The small sample size of nine participants may not fully represent the broader patient population; these findings must be regarded as exploratory. The impact of the patients' ongoing psychotropic medication on the LDAEP results also cannot be overlooked. Unlike conventional LDAEP studies that employ EEG, this study utilized MEG, which might affect comparability with existing literature. Despite these limitations, this study provides meaningful insights into the changes in LDAEP following ECT and signals the importance of conducting larger-scale, more controlled research to elucidate these preliminary observations.

# 5 CONCLUSION

Contrary to our initial hypothesis, ECT paradoxically led to an increase in LDAEP, implying a reduction
in serotonergic activity. Given the complex roles ECT plays in the brain's neurochemistry and the multifaceted nature of LDAEP as a biological marker, our results might not signal a straightforward suppression

of serotonin. They could reflect compensatory adjustments in serotonergic receptor activity or broader
changes encompassing other neurotransmitter systems, neuroplasticity, and neuro-immune interactions.
This unexpected outcome opens avenues for multiple lines of inquiry: the intricate interplay between ECT
and LDAEP, and how they might influence 1) the activity of serotonergic, dopaminergic, glutamatergic,
and GABAergic receptors and transporters; 2) neuroplasticity and BDNF levels in the temporal cortex; and

240 3) levels of the pro-inflammatory cytokine TNF- $\alpha$ .L ooking forward, further investigation is needed to

241 validate the LDAEP as a biomarker of serotonergic neurotransmission and to elucidate ECT's effect on

242 serotonergic activity in the human brain.

# CONFLICT OF INTEREST STATEMENT

Z.-D. Deng is inventor on patents and patent applications on electrical and magnetic brain stimulation
therapy systems held by the National Institutes of Health (NIH), Columbia University, and University of
New Mexico. C. C. Abbot is inventor on patents and patent applications on electrical brain stimulation
therapy systems held by University of New Mexico.

### FUNDING

Z.-D. Deng is supported by the National Institute of Mental Health Intramural Research Program(ZIAMH002955).

## REFERENCES

- 1.Bains N, Abdijadid S. *Major Depressive Disorder* (Treasure Island, FL: StatPearls Publishing) (2024).
   Available from: http://www.ncbi.nlm.nih.gov/books/NBK559078/ [Accessed April 9, 2024].
- 252 2.Hsieh MH. Electroconvulsive therapy for treatment-resistant depression. *Prog Brain Res* 281 (2023)
   253 69–90. doi:10.1016/bs.pbr.2023.01.004.
- 3. Subramanian S, Lopez R, Zorumski CF, Cristancho P. Electroconvulsive therapy in treatment resistant
   depression. *J Neurol Sci* 434 (2022) 120095. doi:10.1016/j.jns.2021.120095.
- 4.Deng ZD, Robins PL, Regenold W, Rohde P, Dannhauer M, Lisanby SH. How electroconvulsive
   therapy works in the treatment of depression: is it the seizure, the electricity, or both?
   *Neuropsychopharmacology* 49 (2024) 150–162. doi:10.1038/s41386-023-01677-2.
- 5. Chen X, Yang H, Cui LB, Li X. Neuroimaging study of electroconvulsive therapy for depression. *Front Psychiatry* 14 (2023) 1170625. doi:10.3389/fpsyt.2023.1170625.
- 6.Rojas M, Ariza D, Ortega A, Riaño Garzón ME, Chávez-Castillo M, Pérez JL, et al. Electroconvulsive
   therapy in psychiatric disorders: A narrative review exploring neuroendocrine-immune therapeutic
   mechanisms and clinical implications. *Int J Mol Sci* 23 (2022) 6918. doi:10.3390/ijms23136918.
- 7. Ousdal OT, Brancati GE, Kessler U, Erchinger V, Dale AM, Abbott C, et al. The neurobiological effects of electroconvulsive therapy studied through magnetic resonance: What have we learned, and where do we go? *Biol Psychiatry* 91 (2022) 540–549. doi:10.1016/j.biopsych.2021.05.023.
- 8.Maffioletti E, Carvalho Silva R, Bortolomasi M, Baune BT, Gennarelli M, Minelli A. Molecular
  biomarkers of electroconvulsive therapy effects and clinical response: Understanding the present to
  shape the future. *Brain Sci* 11 (2021) 1120. doi:10.3390/brainsci11091120.

270 271 272	<b>9</b> .Belge JB, Mulders P, Van Diermen L, Sienaert P, Sabbe B, Abbott CC, et al. Reviewing the neurobiology of electroconvulsive therapy on a micro-, meso-, and macro-level. <i>Prog Neuropsychopharmacol Biol Psychiatry</i> <b>127</b> (2023) 110809. doi:10.1016/j.pnpbp.2023.110809.
273 274 275	<b>10</b> .Cano M, Camprodon JA. Understanding the mechanisms of action of electroconvulsive therapy: Revisiting neuroinflammatory and neuroplasticity hypotheses. <i>JAMA Psychiatry</i> <b>80</b> (2023) 643–644. doi:10.1001/jamapsychiatry.2023.0728.
276 277	<b>11</b> .Delgado PL. Depression: The case for a monoamine deficiency. <i>J Clin Psychiatry</i> <b>61 Suppl 6</b> (2000) 7–11.
278 279	12 .Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and electroconvulsive therapy. <i>J ECT</i> 30 (2014) 116–121. doi:10.1097/YCT.00000000000138.
280 281 282	<ul> <li>13 .Juckel G, Hegerl U, Molnár M, Csépe V, Karmos G. Auditory-evoked potentials as indicator of brain serotonergic activity–first evidence in behaving cats. <i>Biol Psychiatry</i> 41 (1997) 1181–1195. doi:10.1016/s0006-3223(96)00240-5.</li> </ul>
283 284 285 286	14 .Juckel G, Hegerl U, Molnár M, Csépe V, Karmos G. Auditory evoked potentials reflect serotonergic neuronal activity–a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. <i>Neuropsychopharmacology</i> 21 (1999) 710–716. doi:10.1016/S0893-133X(99) 00074-3.
287 288	<b>15</b> .Buchsbaum M. Individual differences in stimulus intensity response. <i>Psychophysiology</i> <b>8</b> (1971) 600–611. doi:10.1111/j.1469-8986.1971.tb00496.x.
289 290 291	16 .Manjarrez G, Hernandez E, Robles A, Hernandez J. N1/P2 component of auditory evoked potential reflect changes of the brain serotonin biosynthesis in rats. <i>Nutr Neurosci</i> 8 (2005) 213–218. doi:10. 1080/10284150500170971.
292 293 294	<ul> <li>17 .Hegerl U, Gallinat J, Juckel G. Event-related potentials. do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? <i>J Affect Disord</i> 62 (2001) 93–100. doi:10.1016/s0165-0327(00)00353-0.</li> </ul>
295 296 297	<ul> <li>18 .Kangas ES, Vuoriainen E, Lindeman S, Astikainen P. Auditory event-related potentials in separating patients with depressive disorders and non-depressed controls: A narrative review. <i>Int J Psychophysiol</i> 179 (2022) 119–142. doi:10.1016/j.ijpsycho.2022.07.003.</li> </ul>
298 299 300 301	<b>19</b> .Roser P, Kawohl W, Juckel G. <i>Chapter 20 - The loudness dependence of auditory evoked potentials as an electrophysiological marker of central serotonergic neurotransmission: Implications for clinical psychiatry and psychopharmacotherapy</i> (Elsevier), <i>Handbook of Behavioral Neuroscience</i> , vol. 31 (2020), 361–374. doi:10.1016/B978-0-444-64125-0.00020-7.
302 303	20 .Pan W, Pan J, Zhao Y, Zhang H, Tang J. Serotonin transporter defect disturbs structure and function of the auditory cortex in mice. <i>Front Neurosci</i> 15 (2021) 749923. doi:10.3389/fnins.2021.749923.
304 305 306	<b>21</b> .Rao D, Basura GJ, Roche J, Daniels S, Mancilla JG, Manis PB. Hearing loss alters serotonergic modulation of intrinsic excitability in auditory cortex. <i>J Neurophysiol</i> <b>104</b> (2010) 2693–2703. doi:10. 1152/jn.01092.2009.
307 308 309	22 .Lee KKY, Soutar CN, Dringenberg HC. Gating of long-term potentiation (LTP) in the thalamocortical auditory system of rats by serotonergic (5-HT) receptors. <i>Brain Res</i> <b>1683</b> (2018) 1–11. doi:10.1016/j. brainres.2018.01.004.
310	23 .Steinberg LJ, Underwood MD, Bakalian MJ, Kassir SA, Mann JJ, Arango V. 5-HT1A receptor, 5-HT2A

receptor and serotonin transporter binding in the human auditory cortex in depression. *J Psychiatry Neurosci* 44 (2019) 294–302. doi:10.1503/jpn.180190.

313 314 315	<b>24</b> .O'Neill BV, Croft RJ, Nathan PJ. The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: Rationale, evaluation and review of findings. <i>Hum Psychopharmacol</i> <b>23</b> (2008) 355–370. doi:10.1002/hup.940.
316 317	<b>25</b> .Zhang M, Siegle GJ. Linking affective and hearing sciences-affective audiology. <i>Trends Hear</i> <b>27</b> (2023) 23312165231208377. doi:10.1177/23312165231208377.
318 319	<b>26</b> .Keesom SM, Hurley LM. Silence, solitude, and serotonin: Neural mechanisms linking hearing loss and social isolation. <i>Brain Sci</i> <b>10</b> (2020) 367. doi:10.3390/brainsci10060367.
320 321	27 .Tang ZQ, Trussell LO. Serotonergic modulation of sensory representation in a central multisensory circuit is pathway specific. <i>Cell Rep</i> 20 (2017) 1844–1854. doi:10.1016/j.celrep.2017.07.079.
322 323	<b>28</b> .Papesh M, Hurley L. Modulation of auditory brainstem responses by serotonin and specific serotonin receptors. <i>Hear Res</i> <b>332</b> (2016) 121–136.
324	29 .Pillai R, Bartlett E, Ananth M, Zhu Z, Yang J, Hajcak Gea. Examining the underpinnings of loudness
325 326	dependence of auditory evoked potentials with positron emission tomography. <i>Neuroimage</i> <b>213</b> (2020) 116733.
327	30 .Christ M, Michael N, Hihn H, Schüttke C, Konrad C, Baune BT, et al. Auditory processing of sine tones
328 329	before, during and after ECT in depressed patients by fMRI. <i>J Neural Transm</i> <b>115</b> (2008) 1199–1211. doi:10.1007/s00702-008-0036-5.
330	31 .Zwanzger P, Zavorotnyy M, Diemer J, Ruland T, Domschke K, Christ M, et al. Auditory processing in
331	remitted major depression: A long-term follow-up investigation using 3T-fMRI. J Neural Transm 119
332	(2012) 1565–1573. doi:10.1007/s00702-012-0871-2.
333	32 .Zweerings J, Zvyagintsev M, Turetsky BI, Klasen M, König AA, Roecher E, et al. Fronto-parietal and
334	temporal brain dysfunction in depression: A fMRI investigation of auditory mismatch processing. <i>Hum</i>
335	Brain Mapp 40 (2019) 3657–3668. doi:10.1002/hbm.24623.
336	<b>33</b> Opitz B, Schröger E, von Cramon DY. Sensory and cognitive mechanisms for preattentive change
337	detection in auditory cortex. Eur J Neurosci <b>21</b> (2003) $551-555$ . doi:10.1111/j.1460-9568.2005.05859.
330	A. 34 Cervantes-Ramírez V Canto-Rustos M. Aquilar Magaña D. Pérez Padilla FA. Góngora-Alfaro II.
340	Pineda IC, et al. Citalopram reduces glutamatergic synaptic transmission in the auditory cortex
341	via activation of 5-HT1A receptors. <i>Neuroreport</i> <b>30</b> (2019) 1316–1322. doi:10.1097/WNR.
342	0000000001366.
343	35 .Timmermann C, Spriggs MJ, Kaelen M, Leech R, Nutt DJ, Moran RJ, et al. LSD modulates effective
344	connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology
345	142 (2018) 251–262. doi:10.1016/j.neuropharm.2017.10.039.
346	36 .Ampuero E, Cerda M, Härtel S, Rubio FJ, Massa S, Cubillos P, et al. Chronic fluoxetine treatment
347	induces maturation-compatible changes in the dendritic arbor and in synaptic responses in the auditory
348	cortex. Front Pharmacol 10 (2019) 804. doi:https://doi.org/10.3389/fphar.2019.00804.
349	37 .Griskova I, Dapsys K, Andruskevicius S, Ruksenas O. Does electroconvulsive therapy (ECT) affect
350 351	ane-2005-1541.
352	38 .Nurminen M, Valkonen-Korhonen M, Mervaala E, Pääkkönen A, Partanen J, Viinamäki H. Enhanced
353	attention-dependent auditory processing by electroconvulsive therapy in psychotic depression. J ECT
354	<b>21</b> (2005) 19–24. doi:10.1097/01.yct.0000158015.88677.bc.
355 356	<ul> <li>39 .Carhart-Harris RL, Nutt DJ. Serotonin and brain function: A tale of two receptors. <i>J Psychopharmacol</i> 31 (2017) 1091–1120. doi:10.1177/0269881117725915.</li> </ul>

- 40. Yatham LN, Liddle PF, Lam RW, Zis AP, Stoessl AJ, Sossi V, et al. Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. *Br J Psychiatry* 196 (2010) 474–478. doi:10.1192/bjp.bp.109.069567.
- 41 .Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, et al. Global
   decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured
   by PET. *Mol Psychiatry* 18 (2013) 93–100. doi:10.1038/mp.2012.93.
- 363 42 .Strome E, Clark C, Zis A, Doudet D. Electroconvulsive shock decreases binding to 5-HT2 receptors
   364 in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone. *Biol* 365 *Psychiatry* 57 (2005) 1004–1010. doi:10.1016/j.biopsych.2005.01.025.
- 366 43 .Saijo T, Takano A, Suhara T, Arakawa R, Okumura M, Ichimiya T, et al. Effect of electroconvulsive
   therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635.
   *Int J Neuropsychopharmacol* 13 (2010) 785–791. doi:10.1017/S1461145709991209.
- 44 .Landau AM, Alstrup AKO, Noer O, Winterdahl M, Audrain H, Møller A, et al. Electroconvulsive
  stimulation differentially affects [11C]MDL100,907 binding to cortical and subcortical 5HT2A
  receptors in porcine brain. *J Psychopharmacol* 33 (2019) 714–721. doi:10.1177/0269881119836212.
- 45 .Hvilsom AST, Lillethorup TP, Iversen P, Doudet DJ, Wegener G, Landau AM. Cortical and striatal
  serotonin transporter binding in a genetic rat model of depression and in response to electroconvulsive
  stimuli. *Eur Neuropsychopharmacol* 29 (2019) 493–500. doi:10.1016/j.euroneuro.2019.02.009.
- 46 .Burnet PW, Sharp T, LeCorre SM, Harrison PJ. Expression of 5-HT receptors and the 5-HT transporter
  in rat brain after electroconvulsive shock. *Neurosci Lett* 277 (1999) 79–82. doi:10.1016/s0304-3940(99)
  00857-5.
- 47 .Li XK, Qiu HT. Current progress in neuroimaging research for the treatment of major depression with
   electroconvulsive therapy. *World J Psychiatry* 12 (2022) 128–139. doi:10.5498/wjp.v12.i1.128.
- 48 .Jiang J, Wang J, Li C. Potential mechanisms underlying the therapeutic effects of electroconvulsive
   therapy. *Neurosci Bull* 33 (2016) 339–347. doi:10.1007/s12264-016-0094-x.
- Abbott CC, Lemke NT, Gopal S, Thomas RJ, Bustillo J, Calhoun VD, et al. Electroconvulsive therapy
   response in major depressive disorder: a pilot functional network connectivity resting state fMRI
   investigation. *Front Psychiatry* 4 (2013) 10. doi:10.3389/fpsyt.2013.00010.
- 50 .Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation:
  automated labeling of neuroanatomical structures in the human brain. *Neuron* 33 (2002) 341–355.
  doi:10.1016/S0896-6273(02)00569-X.
- Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM. Brainstorm: A user-friendly application for
   MEG/EEG analysis. *Comput Intell Neurosci* 2011 (2011) 879716. doi:10.1155/2011/879716.
- 390 52 .Ostermann J, Uhl I, Köhler E, Juckel G, Norra C. The loudness dependence of auditory evoked
   391 potentials and effects of psychopathology and psychopharmacotherapy in psychiatric inpatients. *Hum* 392 *Psychopharmacol* 27 (2012) 595–604. doi:10.1002/hup.2269.
- 393 53 .Obermanns J, Flasbeck V, Steinmann S, Juckel G, Emons B. Investigation of the serotonergic activity
  and the serotonin content in serum and platelet, and the possible role of the serotonin transporter in
  patients with depression. *Behav Sci* 12 (2022) 178. doi:10.3390/bs12060178.
- 54. Uhl I, Gorynia I, Gallinat J, Mulert C, Wutzler A, Heinz A, et al. Is the loudness dependence of
  auditory evoked potentials modulated by the selective serotonin reuptake inhibitor citalopram in healthy
  subjects? *Hum Psychopharmacol* 21 (2006) 463–471. doi:10.1002/hup.803.
- 399 55 .Guille V, Croft RJ, O'Neill BV, Illic S, Phan KL, Nathan PJ. An examination of acute changes in
   400 serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked

- 401 activity: effects of citalopram, escitalopram and sertraline. *Hum Psychopharmacol* 23 (2008) 231–241.
  402 doi:10.1002/hup.922.
- 56 .Oliva J, Leung S, Croft RJ, O'Neill BV, O'Kane J, Stout J, et al. The loudness dependence auditory
  evoked potential is insensitive to acute changes in serotonergic and noradrenergic neurotransmission. *Hum Psychopharmacol* 25 (2010) 423–427. doi:10.1002/hup.1133.
- 406 57 .O'Neill BV, Guille V, Croft RJ, Leung S, Scholes KE, Phan KL, et al. Effects of selective and
  407 combined serotonin and dopamine depletion on the loudness dependence of the auditory evoked
  408 potential (LDAEP) in humans. *Hum Psychopharmacol* 23 (2008) 301–312. doi:10.1002/hup.926.
- 58 .Nathan PJ, Segrave R, Phan KL, O'Neill B, Croft RJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. *Hum Psychopharmacol* 21 (2006) 47–52. doi:10.1002/hup.740.
- 413 59 .Wutzler A, Winter C, Kitzrow W, Uhl I, Wolf RJ, Heinz A, et al. Loudness dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission: simultaneous electrophysiological recordings and in vivo microdialysis in the rat primary auditory cortex. *Neuropsychopharmacology* 33 (2008) 3176–3181. doi:10.1038/npp.2008.42.
- 417 60 .Simmons JG, Nathan PJ, Berger G, Allen NB. Chronic modulation of serotonergic neurotransmission
  418 with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy
  419 participants. *Psychopharmacology* 217 (2011) 101–110. doi:10.1007/s00213-011-2265-9.
- 420 61 .Plein H, Berk M. Changes in the platelet intracellular calcium response to serotonin in patients
  421 with major depression treated with electroconvulsive therapy: State or trait marker status. *Int Clin*422 *Psychopharmacol* 15 (2000) 93–98. doi:10.1097/00004850-200015020-00005.
- 423 62 .Ishihara K, Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT)
  424 on depression. *Jpn J Pharmacol* 80 (1999) 185–189. doi:10.1254/jjp.80.185.
- 425 63 .Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, Möller HJ, et al. Serotonergic dysfunction in
  426 schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.
  427 Schizophr Res 64 (2003) 115–124. doi:10.1016/s0920-9964(03)00016-1.
- 428 64 .Vetulani J, Lebrecht U, Pilc A. Enhancement of responsiveness of the central serotonergic system and
  429 serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. *Eur J Pharmacol* 76
  430 (1981) 81–85. doi:10.1016/0014-2999(81)90012-1.
- 65 .Wyss C, Hitz K, Hengartner MP, Theodoridou A, Obermann C, Uhl I, et al. The loudness dependence
  of auditory evoked potentials (LDAEP) as an indicator of serotonergic dysfunction in patients with
  predominant schizophrenic negative symptoms. *PLoS One* 8 (2013) e68650. doi:10.1371/journal.pone.
  0068650.
- 435 66 .Pauletti C, Mannarelli D, Locuratolo N, Maffucci A, Currà A, Marinelli Lea. Serotonergic central
  436 tone in parkinson's disease with fatigue: Evidence from the loudness dependence of auditory evoked
  437 potentials (ldaep). *Neurosci Lett* 764 (2021) 136242.
- 438 67 .Park E, Park YM, Lee SH, Kim B. The loudness dependence of auditory evoked potentials is associated
  439 with the symptom severity and treatment in boys with attention deficit hyperactivity disorder. *Clin*440 *Psychopharmacol Neurosci* 20 (2022) 514–525.
- 68 .Saijo T, Takano A, Suhara T, Arakawa R, Okumura M, Ichimiya T, et al. Electroconvulsive therapy decreases dopamine D<sub>2</sub> receptor binding in the anterior cingulate in patients with depression: A controlled study using positron emission tomography with radioligand [<sup>1</sup>1C]FLB 457. *J Clin Psychiatry*71 (2010) 793–798. doi:10.4088/JCP.08m04746blu.

- 445 69 .Strome EM, Zis AP, Doudet DJ. Electroconvulsive shock enhances striatal dopamine D1 and D3
  446 receptor binding and improves motor performance in 6-OHDA-lesioned rats. *J Psychiatry Neurosci* 32
  447 (2007) 193–202.
- 70 .Masuoka T, Tateno A, Sakayori T, Tiger M, Kim W, Moriya H, et al. Electroconvulsive therapy
  decreases striatal dopamine transporter binding in patients with depression: A positron emission
  tomography study with [18F]FE-PE2I. *Psychiatry Res Neuroimaging* 301 (2020) 111086. doi:10.1016/
  j.pscychresns.2020.111086.
- 71 .Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y, et al. Efficacy
  of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and
  brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. *Prog Neuropsychopharmacol Biol Psychiatry* 32 (2008) 1185–1190. doi:10.1016/j.pnpbp.2008.02.009.
- 456 72 .Ciranna L. Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission:
  457 implications in physiological functions and in pathology. *Curr Neuropharmacol* 4 (2006) 101–114.
  458 doi:10.2174/157015906776359540.
- 73 .Zhang J, Narr KL, Woods RP, Phillips OR, Alger JR, Espinoza RT. Glutamate normalization with ECT treatment response in major depression. *Mol Psychiatry* 18 (2013) 268–270. doi:10.1038/mp.2012.46.
- 461 74 .Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, et al. Increased cortical
  462 GABA concentrations in depressed patients receiving ECT. *Am J Psychiatry* 160 (2003) 577–579.
  463 doi:10.1176/appi.ajp.160.3.577.
- 464 75 .Esel E, Kose K, Hacimusalar Y, Ozsoy S, Kula M, Candan Z, et al. The effects of electroconvulsive
  therapy on GABAergic function in major depressive patients. *J ECT* 24 (2008) 224–228. doi:10.1097/
  466 YCT.0b013e31815cbaa1.
- 76 .Teichert T. Loudness- and time-dependence of auditory evoked potentials is blunted by the NMDA channel blocker MK-801. *Psychiatry Res* 256 (2017) 202–206. doi:10.1016/j.psychres.2017.06.047.
- 469 77 .Wyss C, Tse DHY, Boers F, Shah NJ, Neuner I, Kawohl W. Association between cortical GABA and
  470 loudness dependence of auditory evoked potentials (LDAEP) in humans. *Int J Neuropsychopharmacol*471 21 (2018) 809–813. doi:10.1093/ijnp/pyy056.
- 472 78 .Deng ZD, Argyelan M, Miller J, Quinn DK, Lloyd M, Jones TR, et al. Electroconvulsive therapy,
  473 electric field, neuroplasticity, and clinical outcomes. *Mol Psychiatry* 27 (2022) 1676–1682. doi:10.
  474 1038/s41380-021-01380-y.
- 475 79 .Argyelan M, Oltedal L, Deng ZD, Wade B, Bikson A Mand Joanlanne, Sanghani S, et al. Electric field causes volumetric changes in the human brain. *Elife* 8 (2019) e49115. doi:10.7554/eLife.49115.
- 477 80 .Pirnia T, Joshi SH, Leaver AM, Vasavada M, Njau S, Woods RP, et al. Electroconvulsive therapy and
  478 structural neuroplasticity in neocortical, limbic and paralimbic cortex. *Transl Psychiatry* 6 (2016) e832.
  479 doi:10.1038/tp.2016.102.
- 480 81 .Pelosof R, dos Santos LA, Farhat LC, Gattaz WF, Talib L, Brunoni AR. BDNF blood levels after
  481 electroconvulsive therapy in patients with mood disorders: An updated systematic review and meta482 analysis. *World J Biol Psychiatry* 24 (2023) 24–33. doi:10.1080/15622975.2022.2058083.
- 483 82 .Park YM, Lee BH, Um TH, Kim S. Serum BDNF levels in relation to illness severity, suicide attempts,
  484 and central serotonin activity in patients with major depressive disorder: A pilot study. *PLoS One* 9
  485 (2014) e91061. doi:10.1371/journal.pone.0091061.
- 486 83 .Gay F, Romeo B, Martelli C, Benyamina A, Hamdani N. Cytokines changes associated with
   487 electroconvulsive therapy in patients with treatment-resistant depression: A meta-analysis. *Psychiatry* 488 *Res* 297 (2021) 113735. doi:10.1016/j.psychres.2021.113735.

- 489 84 .Desfossés CY, Peredo R, Chabot A, Carmel JP, Tremblay PM, Mérette C, et al. The pattern of change in depressive symptoms and inflammatory markers after electroconvulsive therapy: A systematic review.
   491 *J ECT* 37 (2021) 291–297. doi:10.1097/YCT.00000000000782.
- 492 **85** .Lee BH, Park YM, Lee SH, Shim M. Serum levels of tumor necrosis factor- $\alpha$  and loudness dependence
- 493 of auditory evoked potentials at pretreatment and posttreatment in patients with major depressive
- 494 disorder. *Brain Sci* **9** (2019) 253. doi:10.3390/brainsci9100253.